MX2013012486A - Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor). - Google Patents

Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor).

Info

Publication number
MX2013012486A
MX2013012486A MX2013012486A MX2013012486A MX2013012486A MX 2013012486 A MX2013012486 A MX 2013012486A MX 2013012486 A MX2013012486 A MX 2013012486A MX 2013012486 A MX2013012486 A MX 2013012486A MX 2013012486 A MX2013012486 A MX 2013012486A
Authority
MX
Mexico
Prior art keywords
pi3k
mtor
treating lymphoma
pyridopyrimidinone
inhibitors
Prior art date
Application number
MX2013012486A
Other languages
English (en)
Inventor
Arthur Decillis
Joanne Lager
Tal Zaks
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2013012486A publication Critical patent/MX2013012486A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona un método para tratar los cánceres, incluyendo malignidades hematológicas que comprenden administrar de un compuesto de formula I:.
MX2013012486A 2011-04-29 2012-04-27 Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor). MX2013012486A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161480991P 2011-04-29 2011-04-29
US201161493998P 2011-06-07 2011-06-07
US201161566066P 2011-12-02 2011-12-02
PCT/US2012/035442 WO2012149308A1 (en) 2011-04-29 2012-04-27 Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor

Publications (1)

Publication Number Publication Date
MX2013012486A true MX2013012486A (es) 2014-05-28

Family

ID=46062758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012486A MX2013012486A (es) 2011-04-29 2012-04-27 Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor).

Country Status (14)

Country Link
US (1) US20140296265A1 (es)
EP (1) EP2701690A1 (es)
JP (1) JP2014513104A (es)
KR (1) KR20140040726A (es)
CN (1) CN103635183A (es)
AR (1) AR086209A1 (es)
AU (1) AU2012249500A1 (es)
CA (1) CA2834282A1 (es)
EA (1) EA201391606A1 (es)
MX (1) MX2013012486A (es)
TW (1) TW201311683A (es)
UY (1) UY34044A (es)
WO (1) WO2012149308A1 (es)
ZA (1) ZA201307952B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2616442B8 (en) 2010-09-14 2018-10-17 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
CN107375289A (zh) 2011-11-01 2017-11-24 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物
HK1232227A1 (zh) * 2014-07-04 2018-01-05 Lupin Limited 作为pi3k抑制剂的喹嗪酮衍生物
PT3497103T (pt) * 2016-08-15 2021-06-17 Pfizer Inibidores de piridopirimidinona cdk2/4/6

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
EA016945B1 (ru) * 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AR073524A1 (es) * 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
JP5709766B2 (ja) * 2009-03-12 2015-04-30 ジェネンテック， インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
UY33221A (es) * 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
WO2012065019A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha

Also Published As

Publication number Publication date
KR20140040726A (ko) 2014-04-03
AU2012249500A1 (en) 2013-11-28
CA2834282A1 (en) 2012-11-01
US20140296265A1 (en) 2014-10-02
UY34044A (es) 2012-11-30
JP2014513104A (ja) 2014-05-29
AR086209A1 (es) 2013-11-27
EA201391606A1 (ru) 2016-01-29
TW201311683A (zh) 2013-03-16
WO2012149308A1 (en) 2012-11-01
CN103635183A (zh) 2014-03-12
ZA201307952B (en) 2014-06-25
EP2701690A1 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
EA201890768A2 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
MX351892B (es) Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso.
PH12012501719A1 (en) Compounds for immunoproteasome inhibition
PH12017502141A1 (en) Compounds and their methods of use
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX2013011333A (es) Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX2013012486A (es) Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor).
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
IN2014CN02671A (es)
MX350868B (es) Medicamentos y metodos para tratar cancer.